Eterna Therapeutics (ERNA)
NASDAQ:ERNA
ERNA Stock Chart & Stats
$0.21
-$0.01(-3.03%)
At close: 4:00 PM EST
$0.21
-$0.01(-3.03%)
Day’s Range― - ―
52-Week Range$3.18 - $71.48
Previous Close$0.34
Volume440.10K
Average Volume (3M)147.10K
Market Cap
$7.35M
Enterprise Value-$6.87M
Total Cash (Recent Filing)$9.18M
Total Debt (Recent Filing)$389.00K
Price to Earnings (P/E)―
Beta1.93
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,166,333
10 Day Avg. Volume52,764
30 Day Avg. Volume147,105
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)3.15
Price to Sales (P/S)0.00
P/FCF Ratio-1.07
Enterprise Value/Market Cap-0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit79.91
Enterprise Value/Ebitda0.42
Forecast
1Y Price Target
$30.00Price Target Upside14185.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Eterna Therapeutics News
ERNA FAQ
What was Eterna Therapeutics’s price range in the past 12 months?
Eterna Therapeutics lowest stock price was $3.18 and its highest was $71.47 in the past 12 months.
What is Eterna Therapeutics’s market cap?
Eterna Therapeutics’s market cap is $7.35M.
When is Eterna Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Eterna Therapeutics’s earnings last quarter?
Currently, no data Available
Is Eterna Therapeutics overvalued?
According to Wall Street analysts Eterna Therapeutics’s price is currently Undervalued.
Does Eterna Therapeutics pay dividends?
Eterna Therapeutics does not currently pay dividends.
What is Eterna Therapeutics’s EPS estimate?
Eterna Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eterna Therapeutics have?
Eterna Therapeutics has 1,166,333 shares outstanding.
What happened to Eterna Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Eterna Therapeutics?
Currently, no hedge funds are holding shares in ERNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eterna Therapeutics
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
ERNA Stock 12 Month Forecast
Average Price Target
$30.00
▲(14185.71% Upside)
Technical Analysis
Kiora Pharmaceuticals
―
KALA BIO
―
Creative Medical Technology Holdings
―
Aprea Therapeutics
―
IN8bio
―
Ownership Overview
23.25% Insiders
0.10% Mutual Funds
0.03% Other Institutional Investors
76.52% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---